布地奈德联合异丙托溴铵雾化治疗COPD急性加重期的效果评价(1)
摘 要：目的 研究在COPD急性加重期患者中予以异丙托溴铵与布地奈德联合雾化治疗的临床效果。方法 选取我院自2015年11月～2016年11月收治的56例COPD急性加重期患者，依据随机数字表法随机分为参照组和实验组，每组28例。参照组采取常规治疗干预，实验组采取异丙托溴铵与布地奈德联合雾化治疗，观察两组患者FEV1、FEV1/FVC、呼吸困难评分以及总有效率。结果 实验组总有效率为96.42%，高于参照组的75.00%，两组相比差异具有统计学意义(P<0.05)；实验组患者FEV1、FEV1/FVC分别为(64.35±2.87)%、(66.54±3.11)%，高于参照组的(53.21±3.14)%、(51.24±4.17)%，两组相比差异具有统计学意义(P<0.05)。实验组呼吸困难评分为(1.35±0.21)分，低于参照组的(2.23±0.31)分，差异具有统计学意义(P<0.05)。结论 异丙托溴铵与布地奈德联合雾化治疗COPD急性加重期患者，疗效显著，可以改善肺功能，改善患者生存质量，值得广泛应用。
关键词：布地奈德；异丙托溴；铵雾化；COPD；急性加重期
, 百拇医药
中图分类号：R563.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.048
文章编号：1006-1959(2018)07-0141-02
Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD
MA Jian-juan
(Department of Internal Medicine，Tianjin Jinghai Women and Children Health Center，Tianjin 301600，China)
Abstract：Objective To study the clinical effect of combined atomization of ipratropium and budesonide in patients with acute exacerbation of COPD.Methods From November 2015 to November 2016，56 patients with acute exacerbation of COPD were randomly divided into control group and experimental group with 28 cases in each group.The control group was treated with routine therapy，the experimental group was treated by combined atomization of isoprotopril and budesonide.The FEV1/FEV1/FVC，dyspnea score and total effective rate were observed in the two groups.Results The total effective rate in the experimental group was 96.42%， which was higher than 75.00% in the reference group，the difference between the two groups was statistically significant(P<0.05).The FEV1，FEV1/FVC in the experimental group were(64.35±2.87)%，respectively(66.54±3.11)%，higher than the reference group(53.21±3.14)%，(51.24±4.17)%，the difference between the two groups was statistically significant(P<0.05).The dyspnea score in the experimental group was(1.35±0.21)points，which was lower than that in the reference group (2.23±0.31)points，the difference was statistically significant(P<0.05).Conclusion The combination of ipratropium bromide and budesonide in the treatment of patients with acute exacerbation of COPD has significant curative effect，can improve lung function，improve the quality of life of patients，and is worthy of extensive application.
, http://www.100md.com
Key words：Budesonide；Ipratropium bromide；Ammonium atomization；COPD；Acute exacerbation
慢性阻塞性肺疾病(chronic obstructive pulmonary diseases，COPD)是慢性氣道炎症性疾病，加重期主要表现包括胸闷、气促加重、喘息等现象[1]，慢性阻塞性肺疾病极有可能损伤气道壁继而引发气流受阻，属于不可逆性病变。在临床上，治疗急性加重期COPD的主要药物为支气管扩张剂和糖皮质激素类药物等。为了进一步研究布地奈德联合异丙托溴铵雾化治疗急性加重期COPD的临床效果，选取我院2015年11月～2016年11月收治的56例COPD急性加重期患者进行研究，现将治疗结果予以报道。, 百拇医药(马建娟)
关键词：布地奈德；异丙托溴；铵雾化；COPD；急性加重期
, 百拇医药
中图分类号：R563.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.048
文章编号：1006-1959(2018)07-0141-02
Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD
MA Jian-juan
(Department of Internal Medicine，Tianjin Jinghai Women and Children Health Center，Tianjin 301600，China)
Abstract：Objective To study the clinical effect of combined atomization of ipratropium and budesonide in patients with acute exacerbation of COPD.Methods From November 2015 to November 2016，56 patients with acute exacerbation of COPD were randomly divided into control group and experimental group with 28 cases in each group.The control group was treated with routine therapy，the experimental group was treated by combined atomization of isoprotopril and budesonide.The FEV1/FEV1/FVC，dyspnea score and total effective rate were observed in the two groups.Results The total effective rate in the experimental group was 96.42%， which was higher than 75.00% in the reference group，the difference between the two groups was statistically significant(P<0.05).The FEV1，FEV1/FVC in the experimental group were(64.35±2.87)%，respectively(66.54±3.11)%，higher than the reference group(53.21±3.14)%，(51.24±4.17)%，the difference between the two groups was statistically significant(P<0.05).The dyspnea score in the experimental group was(1.35±0.21)points，which was lower than that in the reference group (2.23±0.31)points，the difference was statistically significant(P<0.05).Conclusion The combination of ipratropium bromide and budesonide in the treatment of patients with acute exacerbation of COPD has significant curative effect，can improve lung function，improve the quality of life of patients，and is worthy of extensive application.
, http://www.100md.com
Key words：Budesonide；Ipratropium bromide；Ammonium atomization；COPD；Acute exacerbation
慢性阻塞性肺疾病(chronic obstructive pulmonary diseases，COPD)是慢性氣道炎症性疾病，加重期主要表现包括胸闷、气促加重、喘息等现象[1]，慢性阻塞性肺疾病极有可能损伤气道壁继而引发气流受阻，属于不可逆性病变。在临床上，治疗急性加重期COPD的主要药物为支气管扩张剂和糖皮质激素类药物等。为了进一步研究布地奈德联合异丙托溴铵雾化治疗急性加重期COPD的临床效果，选取我院2015年11月～2016年11月收治的56例COPD急性加重期患者进行研究，现将治疗结果予以报道。, 百拇医药(马建娟)